March 24, 2022 07:29 AM EDT

AstraZeneca’s Imfinzi stumbles in cervical cancer, leaving Merck’s Keytruda dominant

After bringing AstraZeneca a steady streak of wins in recent months, the PD-L1 drug Imfinzi has come up empty on the latest Phase …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As­traZeneca’s Imfinzi stum­bles in cer­vi­cal can­cer, leav­ing Mer­ck’s Keytru­da dom­i­nant